Invivoscribe's subsidiary, the Laboratory for Personalized Molecular Medicine (LabPMM), has secured New York State (NYS) approval for the NPM1 MRD Assay, marking an advancement to combat acute ...

The Advertising Research Foundation (ARF) today announced the release of the ARF Handbook for Using AI in Advertising Research (2025), a comprehensive guide that explores how artificial ...

NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases, 1 stable over time, 2 and, if present in blood at allele fractions ≥0.01% ...

In chronic lymphocytic leukemia (CLL), the mechanisms controlling cell growth and proliferation in the presence of NOTCH1 mutations remain largely unexplored. By performing a gene expression ...

Kura Oncology and Kyowa Kirin announce FDA acceptance and Priority Review of New Drug Application for ziftomenib in adults with relapsed or refractory NPM1-mutant AML. News release. Kura Oncology.

The NPM1 mutation affects about 30% of all AML patients. In almost half of those patients, relapse or resistance to standard treatments occurs within a year of treatment.

Here we present the primary analysis for NPM1-m patients (pts) treated with ziftomenib 600 mg QD in the pivotal KOMET-001 study. Methods: KOMET-001 (NCT04067336) is a multicenter, open-label phase 1/2 ...

Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine ® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD ...